Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 3/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.41 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495892 | 0.88 | HPGDS (0.45) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16495367 | 0.88 | HPGDS (0.56) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16495474 | 0.87 | MCHR1 (0.52) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16495554 | 0.87 | HPGDS (0.58) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16495808 | 0.86 | HPGDS (0.51) | HPGDSPRKACGEGLN1 | |
| SCHEMBL16495480 | 0.83 | HPGDS (0.55) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16496086 | 0.83 | HPGDS (0.57) | HPGDSHTR2CMCHR1CDC7CDK19 | |
| SCHEMBL16495766 | 0.81 | HPGDS (0.57) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16495991 | 0.81 | HPGDS (0.57) | HPGDSHTR2CMCHR1GABRA5BAZ2B | |
| SCHEMBL16496233 | 0.79 | HPGDS (0.58) | HPGDSGABRA5BAZ2BWNT3AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885HTR2C 3209/4885MCHR1 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.